Biomedical Manufacturing, Commonwealth Scientific and Industrial Research Organisation, 343 Royal Parade, Parkville, Victoria, 3052, Australia.
CSIRO Synthetic Biology Future Science Platform, GPO Box 1700, Canberra, ACT, 2601, Australia.
Sci Rep. 2021 Mar 4;11(1):5247. doi: 10.1038/s41598-021-84551-9.
Puromycin and the Streptomyces alboniger-derived puromycin N-acetyltransferase (PAC) enzyme form a commonly used system for selecting stably transfected cultured cells. The crystal structure of PAC has been solved using X-ray crystallography, revealing it to be a member of the GCN5-related N-acetyltransferase (GNAT) family of acetyltransferases. Based on structures in complex with acetyl-CoA or the reaction products CoA and acetylated puromycin, four classes of mutations in and around the catalytic site were designed and tested for activity. Single-residue mutations were identified that displayed a range of enzymatic activities, from complete ablation to enhanced activity relative to wild-type (WT) PAC. Cell pools of stably transfected HEK293 cells derived using two PAC mutants with attenuated activity, Y30F and A142D, were found to secrete up to three-fold higher levels of a soluble, recombinant target protein than corresponding pools derived with the WT enzyme. A third mutant, Y171F, appeared to stabilise the intracellular turnover of PAC, resulting in an apparent loss of selection stringency. Our results indicate that the structure-guided manipulation of PAC function can be utilised to enhance selection stringency for the derivation of mammalian cell lines secreting elevated levels of recombinant proteins.
嘌呤霉素和来自链霉菌属的嘌呤霉素 N-乙酰转移酶(PAC)酶形成了一种常用于选择稳定转染的培养细胞的常用系统。通过 X 射线晶体学已经解决了 PAC 的晶体结构,揭示它是 GCN5 相关 N-乙酰转移酶(GNAT)家族乙酰转移酶的成员。基于与乙酰辅酶 A 或反应产物辅酶 A 和乙酰化嘌呤霉素复合物的结构,设计并测试了催化位点周围和内部的四类突变以检测其活性。鉴定出单个残基突变,其表现出一系列酶活性,从完全缺失到相对于野生型(WT)PAC 的增强活性。使用两种活性减弱的 PAC 突变体 Y30F 和 A142D 衍生的稳定转染 HEK293 细胞池发现,分泌的可溶性重组靶蛋白水平比用 WT 酶衍生的相应池高 3 倍。第三个突变体 Y171F 似乎稳定了 PAC 的细胞内周转率,导致选择严格性的明显丧失。我们的结果表明,可以利用基于结构的 PAC 功能操作来增强选择严格性,从而衍生分泌高水平重组蛋白的哺乳动物细胞系。